AAH HOLDINGS TO DIVEST SOME BUSINESS

17 May 1992

UK pharmaceutical wholesaler AAH Holdings has been told, after a Monopolies and Mergers Commission report, that it must divest some of its business, which expanded with the acquisition of Medicopharma NV, because this has stifled competition.

The Commission reportedly concluded that last year's takeover of the Medico-pharma operations led to a reduction in competition in the Grampian and High-land regions of Scotland. However, it did not believe that competition would be affected significantly at the national level. It has suggested that AAH should divest a business which is as close as possible to that carried on by Medicopharma UK (pre-takeover) from its Aberdeen depot.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight